Runben Biotechnology (603193.SH) has announced a forecasted increase, with an expected annual net profit of 300 million to 310 million yuan, a year-on-year growth of 32.73% to 37.15%.

Runben Biotechnology (603193.SH) disclosed its performance forecast for the year 2024, with the company expecting a net profit attributable to the owners of the parent company of 3 billion to 3.1 billion yuan, a year-on-year increase of 32.73% to 37.15%. During the reporting period, the company actively expanded its online and offline channels, increased investment in research and development, further expanded the categories of baby and child care and mosquito repellent products, enriched the product matrix, and significantly improved the overall profitability level of the company.